Please assess the completion status of the following clinical trial:

Trial Title: A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~2. Presence of an active hematological malignancy.~3. Presence of measurable disease.~4. Hematological malignancy has been previously treated, has relapsed after or progressed during prior therapy, and has limited potential for benefit from currently available therapy including hematopoietic stem cell transplantation.~5. At least 2 weeks post any treatments/therapies at the time of first dose.~6. Adequate bone marrow function.~7. Adequate hepatic function.~8. Adequate renal function.~9. Normal coagulation panel.~10. Negative antiviral serology.~11. Willingness to use effective contraception.~Exclusion Criteria:~1. Central nervous system malignancy~2. Gastrointestinal disease~3. Significant cardiovascular disease~4. Significant ECG abnormalities.~5. Ongoing risk for bleeding due to active peptic ulcer disease, bleeding diathesis or requirement for systemic anticoagulation~6. Ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infections)~7. Pregnancy or breastfeeding.~8. Major surgery within 4 weeks before the start of study therapy.~9. Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids~10. Use of drugs that could prolong the QT interval within 7 days before the start of study therapy.~11. Use of drugs that might pose a risk of a drug-drug interaction within 2-7 days before the start of study therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tomivosertib (eFT-508) Escalation Cohort (Type: EXPERIMENTAL): This portion of the study will evaluate the safety and pharmacology of a range of Tomivosertib (eFT-508) doses administered daily in subjects with previously treated lymphomas
- Tomivosertib (eFT-508) Expansion Cohort (Type: EXPERIMENTAL): This portion of the study provides cohort expansion to further explore the safety, pharmacology, and clinical activity of a single dose level of Tomivosertib (eFT-508) monotherapy in subjects with specific previously treated lymphomas

Based on this trial design, predict the completion outcome and termination type (if applicable).